127 related articles for article (PubMed ID: 8556394)
21. An endogenously synthesized decamer peptide efficiently primes cytotoxic T cells specific for the HIV-1 envelope glycoprotein.
Bergmann C; Stohlmann SA; McMillan M
Eur J Immunol; 1993 Nov; 23(11):2777-81. PubMed ID: 7693478
[TBL] [Abstract][Full Text] [Related]
22. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
[TBL] [Abstract][Full Text] [Related]
23. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
[TBL] [Abstract][Full Text] [Related]
24. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
25. Human CD4+ T cells can discriminate the molecular and structural context of T epitopes of HIV gp120 and HIV p66.
Manca F; Fenoglio D; Valle MT; Li Pira G; Kunkl A; Ferraris A; Saverino D; Lancia F; Mortara L; Lozzi L
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jul; 9(3):227-37. PubMed ID: 7540488
[TBL] [Abstract][Full Text] [Related]
26. Cross-reactive T-cell proliferative responses to V3 peptides corresponding to different geographical HIV-1 isolates in HIV-seropositive individuals.
Nehete PN; Johnson PC; Schapiro SJ; Arlinghaus RB; Sastry KJ
J Clin Immunol; 1996 Mar; 16(2):115-24. PubMed ID: 8690775
[TBL] [Abstract][Full Text] [Related]
27. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.
Laakso MM; Lee FH; Haggarty B; Agrawal C; Nolan KM; Biscone M; Romano J; Jordan AP; Leslie GJ; Meissner EG; Su L; Hoxie JA; Doms RW
PLoS Pathog; 2007 Aug; 3(8):e117. PubMed ID: 17722977
[TBL] [Abstract][Full Text] [Related]
28. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1.
Vancott TC; Polonis VR; Loomis LD; Michael NL; Nara PL; Birx DL
AIDS Res Hum Retroviruses; 1995 Nov; 11(11):1379-91. PubMed ID: 8573396
[TBL] [Abstract][Full Text] [Related]
29. Molecular analysis of the same HIV peptide functionally binding to both a class I and a class II MHC molecule.
Takeshita T; Takahashi H; Kozlowski S; Ahlers JD; Pendleton CD; Moore RL; Nakagawa Y; Yokomuro K; Fox BS; Margulies DH
J Immunol; 1995 Feb; 154(4):1973-86. PubMed ID: 7530749
[TBL] [Abstract][Full Text] [Related]
30. CD4+ T-cell recognition of diverse clade B HIV-1 isolates.
Fernandez MH; Fidler SJ; Pitman RJ; Weber JN; Rees AD
AIDS; 1997 Mar; 11(3):281-8. PubMed ID: 9147418
[TBL] [Abstract][Full Text] [Related]
31. Improved humoral and cellular immune responses against the gp120 V3 loop of HIV-1 following genetic immunization with a chimeric DNA vaccine encoding the V3 inserted into the hepatitis B surface antigen.
Fomsgaard A; Nielsen HV; Bryder K; Nielsen C; Machuca R; Bruun L; Hansen J; Buus S
Scand J Immunol; 1998 Apr; 47(4):289-95. PubMed ID: 9600309
[TBL] [Abstract][Full Text] [Related]
32. Antigenicity of three synthetic peptides from the C-terminus of HIV-1 gp 120 correlates with the fragmentation pattern obtained in FAB mass spectrometry.
Streckert HJ; Weber C; Müller D
Intervirology; 1993; 36(3):128-33. PubMed ID: 7512081
[TBL] [Abstract][Full Text] [Related]
33. An HIV-1 envelope protein vaccine elicits a functionally complex human CD4+ T cell response that includes cytolytic T lymphocytes.
Stanhope PE; Liu AY; Pavlat W; Pitha PM; Clements ML; Siliciano RF
J Immunol; 1993 May; 150(10):4672-86. PubMed ID: 8097759
[TBL] [Abstract][Full Text] [Related]
34. Identification of T-cell epitopes without B-cell activity in the first and second conserved regions of the HIV Env protein.
Sastry KJ; Arlinghaus RB
AIDS; 1991 Jun; 5(6):699-707. PubMed ID: 1715718
[TBL] [Abstract][Full Text] [Related]
35. Primary in vitro sensitization of human T-helper lymphocytes by peptides derived from the V3 loop of human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein.
Billaud JN; Yagello M; Gluckman JC
Vaccine; 1994 Jan; 12(1):46-55. PubMed ID: 8303940
[TBL] [Abstract][Full Text] [Related]
36. Fine analysis of immunoreactivity of V3 peptides: antibodies specific for V3 domain of laboratory HIV type 1 strains recognize multiple V3 sequences synthesized from field HIV type 1 isolates.
Boudet F; Lasarte JJ; Sarobe P; Borras-Cuesta F; Theze J
AIDS Res Hum Retroviruses; 1996 Dec; 12(18):1671-9. PubMed ID: 8959242
[TBL] [Abstract][Full Text] [Related]
37. T-cell receptor-mediated anergy of a human immunodeficiency virus (HIV) gp120-specific CD4(+) cytotoxic T-cell clone, induced by a natural HIV type 1 variant peptide.
Bouhdoud L; Villain P; Merzouki A; Arella M; Couture C
J Virol; 2000 Mar; 74(5):2121-30. PubMed ID: 10666241
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity of synthetic peptides corresponding to various epitopes of the human immunodeficiency virus envelope protein.
Zaghouani H; Hall B; Shah H; Bona C
Adv Exp Med Biol; 1991; 303():53-62. PubMed ID: 1725238
[No Abstract] [Full Text] [Related]
39. Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.
Pincus SH; Messer KG; Schwartz DH; Lewis GK; Graham BS; Blattner WA; Fisher G
J Clin Invest; 1993 May; 91(5):1987-96. PubMed ID: 7683694
[TBL] [Abstract][Full Text] [Related]
40. Enhanced activation of human T cell clones specific for virus-like particles expressing the HIV V3 loop in the presence of HIV V3 loop-specific polyclonal antibodies.
Peifang S; Pira GL; Fenoglio D; Harris S; Costa MG; Venturino V; Dessì V; Layton G; Laman J; Huisman JG
Clin Exp Immunol; 1994 Sep; 97(3):361-6. PubMed ID: 7915974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
